TWELVE-YEAR FOLLOW-UP OF ARTIFLEX PHAKIC INTRAOCULAR LENSES AS AN EFFECTIVE LONG TERM REFRACTIVE SOLUTION FOR MYOPIA.

Artiflex phakic intraocular lenses (pIOL) as an effective long term refractive solution for myopia. Long-term visual and physiological safety and stability results of Artiflex Myopia phakic intraocular lenses (pIOL) throughout an 8 & 12-year follow-up will be presented.

Retrospective cohort study.

A total of 47 eyes underwent Artiflex Myopia implantation for the correction of myopic refractive error. Follow-up evaluations were performed 1, 3, 5, 8 and 12 years after surgery. Preoperative and postoperative data included corrected and uncorrected distance visual acuity (CDVA, UDVA), manifest refraction, endothelial cell density (ECD) and cell morphology, anterior chamber depth (ACD) and intraocular pressure (IOP) assessments. Efficacy and safety indexes were analyzed.

Mean CDVA and UDVA significantly improved from preoperative to 1 year after implantation, and then it remained stable over the 8 year follow-up. The efficacy and safety indexes after 8 years were 0.94 ± 0.16 and 1.07 ± 0.18. The spherical equivalent (SE) significantly improved after surgery. SE refractive components showed no changes between postoperative visits. A total ECD loss of 4.8% (p < 0.001) was found after 8 years. Results on the 12 year follow-up are now being analyzed and will be added to the presentation.

Artiflex Myopia pIOLs are a safe, efficient and predictable option for the correction of myopia.